Recent submissions

  • Early enrichment of ESR1 mutations and the impact on gene expression in primary breast cancer treated with aromatase inhibitors in the pre-surgical setting 

    Dowsett, M; Ferreira Leal, M; Haynes, B; Schuster, E; Yeo, B; Afentakis, M; Zabaglo, L; Martins, V; Buus, R; Dodson, A; Cheang, M; Smith, I; Martin, L-A
  • Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. 

    Leung, SCY; Nielsen, TO; Zabaglo, LA; Arun, I; Badve, SS; Bane, AL; Bartlett, JMS; Borgquist, S; Chang, MC; Dodson, A; Ehinger, A; Fineberg, S; Focke, CM; Gao, D; Gown, AM; Gutierrez, C; Hugh, JC; Kos, Z; Laenkholm, A-V; Mastropasqua, MG; Moriya, T; Nofech-Mozes, S; Osborne, CK; Penault-Llorca, FM; Piper, T; Sakatani, T; Salgado, R; Starczynski, J; Sugie, T; van der Vegt, B; Viale, G; Hayes, DF; McShane, LM; Dowsett, M; International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group (BIG-NABCG) (2019-08)
    AIMS: The nuclear proliferation marker Ki67 assayed by immunohistochemistry has multiple potential uses in breast cancer, but an unacceptable level of interlaboratory variability has hampered its clinical utility. The ...
  • Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer. 

    Abubakar, M; Figueroa, J; Ali, HR; Blows, F; Lissowska, J; Caldas, C; Easton, DF; Sherman, ME; Garcia-Closas, M; Dowsett, M; Pharoah, PD (2019-04-11)
    Although most women with luminal breast cancer do well on endocrine therapy alone, some will develop fatal recurrence thereby necessitating the need to prospectively determine those for whom additional cytotoxic therapy ...
  • Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. 

    Dunning, AM; Michailidou, K; Kuchenbaecker, KB; Thompson, D; French, JD; Beesley, J; Healey, CS; Kar, S; Pooley, KA; Lopez-Knowles, E; Dicks, E; Barrowdale, D; Sinnott-Armstrong, NA; Sallari, RC; Hillman, KM; Kaufmann, S; Sivakumaran, H; Moradi Marjaneh, M; Lee, JS; Hills, M; Jarosz, M; Drury, S; Canisius, S; Bolla, MK; Dennis, J; Wang, Q; Hopper, JL; Southey, MC; Broeks, A; Schmidt, MK; Lophatananon, A; Muir, K; Beckmann, MW; Fasching, PA; Dos-Santos-Silva, I; Peto, J; Sawyer, EJ; Tomlinson, I; Burwinkel, B; Marme, F; Guénel, P; Truong, T; Bojesen, SE; Flyger, H; González-Neira, A; Perez, JI; Anton-Culver, H; Eunjung, L; Arndt, V; Brenner, H; Meindl, A; Schmutzler, RK; Brauch, H; Hamann, U; Aittomäki, K; Blomqvist, C; Ito, H; Matsuo, K; Bogdanova, N; Dörk, T; Lindblom, A; Margolin, S; Kosma, VM; Mannermaa, A; Tseng, CC; Wu, AH; Lambrechts, D; Wildiers, H; Chang-Claude, J; Rudolph, A; Peterlongo, P; Radice, P; Olson, JE; Giles, GG; Milne, RL; Haiman, CA; Henderson, BE; Goldberg, MS; Teo, SH; Yip, CH; Nord, S; Borresen-Dale, AL; Kristensen, V; Long, J; Zheng, W; Pylkäs, K; Winqvist, R; Andrulis, IL; Knight, JA; Devilee, P; Seynaeve, C; Figueroa, J; Sherman, ME; Czene, K; Darabi, H; Hollestelle, A; van den Ouweland, AM; Humphreys, K; Gao, YT; Shu, XO; Cox, A; Cross, SS; Blot, W; Cai, Q; Ghoussaini, M; Perkins, BJ; Shah, M; Choi, JY; Kang, D; Lee, SC; Hartman, M; Kabisch, M; Torres, D; Jakubowska, A; Lubinski, J; Brennan, P; Sangrajrang, S; Ambrosone, CB; Toland, AE; Shen, CY; Wu, PE; Orr, N; Swerdlow, A; McGuffog, L; Healey, S; Lee, A; Kapuscinski, M; John, EM; Terry, MB; Daly, MB; Goldgar, DE; Buys, SS; Janavicius, R; Tihomirova, L; Tung, N; Dorfling, CM; van Rensburg, EJ; Neuhausen, SL; Ejlertsen, B; Hansen, TV; Osorio, A; Benitez, J; Rando, R; Weitzel, JN; Bonanni, B; Peissel, B; Manoukian, S; Papi, L; Ottini, L; Konstantopoulou, I; Apostolou, P; Garber, J; Rashid, MU; Frost, D; Izatt, L; Ellis, S; Godwin, AK; Arnold, N; Niederacher, D; Rhiem, K; Bogdanova-Markov, N; Sagne, C; Stoppa-Lyonnet, D; Damiola, F; Sinilnikova, OM; Mazoyer, S; Isaacs, C; Claes, KB; De Leeneer, K; de la Hoya, M; Caldes, T; Nevanlinna, H; Khan, S; Mensenkamp, AR; Hooning, MJ; Rookus, MA; Kwong, A; Olah, E; Diez, O; Brunet, J; Pujana, MA; Gronwald, J; Huzarski, T; Barkardottir, RB; Laframboise, R; Soucy, P; Montagna, M; Agata, S; Teixeira, MR; Park, SK; Lindor, N; Couch, FJ; Tischkowitz, M; Foretova, L; Vijai, J; Offit, K; Singer, CF; Rappaport, C; Phelan, CM; Greene, MH; Mai, PL; Rennert, G; Imyanitov, EN; Hulick, PJ; Phillips, KA; Piedmonte, M; Mulligan, AM; Glendon, G; Bojesen, A; Thomassen, M; Caligo, MA; Yoon, SY; Friedman, E; Laitman, Y; Borg, A; von Wachenfeldt, A; Ehrencrona, H; Rantala, J; Olopade, OI; Ganz, PA; Nussbaum, RL; Gayther, SA; Nathanson, KL; Domchek, SM; Arun, BK; Mitchell, G; Karlan, BY; Lester, J; Maskarinec, G; Woolcott, C; Scott, C; Stone, J; Apicella, C; Tamimi, R; Luben, R; Khaw, KT; Helland, Å; Haakensen, V; Dowsett, M; Pharoah, PD; Simard, J; Hall, P; García-Closas, M; Vachon, C; Chenevix-Trench, G; Antoniou, AC; Easton, DF; Edwards, SL (2016-04)
    We analyzed 3,872 common genetic variants across the ESR1 locus (encoding estrogen receptor α) in 118,816 subjects from three international consortia. We found evidence for at least five independent causal variants, each ...
  • Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. 

    Ferreira, MA; Gamazon, ER; Al-Ejeh, F; Aittomäki, K; Andrulis, IL; Anton-Culver, H; Arason, A; Arndt, V; Aronson, KJ; Arun, BK; Asseryanis, E; Azzollini, J; Balmaña, J; Barnes, DR; Barrowdale, D; Beckmann, MW; Behrens, S; Benitez, J; Bermisheva, M; Białkowska, K; Blomqvist, C; Bogdanova, NV; Bojesen, SE; Bolla, MK; Borg, A; Brauch, H; Brenner, H; Broeks, A; Burwinkel, B; Caldés, T; Caligo, MA; Campa, D; Campbell, I; Canzian, F; Carter, J; Carter, BD; Castelao, JE; Chang-Claude, J; Chanock, SJ; Christiansen, H; Chung, WK; Claes, KBM; Clarke, CL; EMBRACE Collaborators; GC-HBOC Study Collaborators; GEMO Study Collaborators; Couch, FJ; Cox, A; Cross, SS; Czene, K; Daly, MB; de la Hoya, M; Dennis, J; Devilee, P; Diez, O; Dörk, T; Dunning, AM; Dwek, M; Eccles, DM; Ejlertsen, B; Ellberg, C; Engel, C; Eriksson, M; Fasching, PA; Fletcher, O; Flyger, H; Friedman, E; Frost, D; Gabrielson, M; Gago-Dominguez, M; Ganz, PA; Gapstur, SM; Garber, J; García-Closas, M; García-Sáenz, JA; Gaudet, MM; Giles, GG; Glendon, G; Godwin, AK; Goldberg, MS; Goldgar, DE; González-Neira, A; Greene, MH; Gronwald, J; Guénel, P; Haiman, CA; Hall, P; Hamann, U; He, W; Heyworth, J; Hogervorst, FBL; Hollestelle, A; Hoover, RN; Hopper, JL; Hulick, PJ; Humphreys, K; Imyanitov, EN; ABCTB Investigators; HEBON Investigators; BCFR Investigators; Isaacs, C; Jakimovska, M; Jakubowska, A; James, PA; Janavicius, R; Jankowitz, RC; John, EM; Johnson, N; Joseph, V; Karlan, BY; Khusnutdinova, E; Kiiski, JI; Ko, Y-D; Jones, ME; Konstantopoulou, I; Kristensen, VN; Laitman, Y; Lambrechts, D; Lazaro, C; Leslie, G; Lester, J; Lesueur, F; Lindström, S; Long, J; Loud, JT; Lubiński, J; Makalic, E; Mannermaa, A; Manoochehri, M; Margolin, S; Maurer, T; Mavroudis, D; McGuffog, L; Meindl, A; Menon, U; Michailidou, K; Miller, A; Montagna, M; Moreno, F; Moserle, L; Mulligan, AM; Nathanson, KL; Neuhausen, SL; Nevanlinna, H; Nevelsteen, I; Nielsen, FC; Nikitina-Zake, L; Nussbaum, RL; Offit, K; Olah, E; Olopade, OI; Olsson, H; Osorio, A; Papp, J; Park-Simon, T-W; Parsons, MT; Pedersen, IS; Peixoto, A; Peterlongo, P; Pharoah, PDP; Plaseska-Karanfilska, D; Poppe, B; Presneau, N; Radice, P; Rantala, J; Rennert, G; Risch, HA; Saloustros, E; Sanden, K; Sawyer, EJ; Schmidt, MK; Schmutzler, RK; Sharma, P; Shu, X-O; Simard, J; Singer, CF; Soucy, P; Southey, MC; Spinelli, JJ; Spurdle, AB; Stone, J; Swerdlow, AJ; Tapper, WJ; Taylor, JA; Teixeira, MR; Terry, MB; Teulé, A; Thomassen, M; Thöne, K; Thull, DL; Tischkowitz, M; Toland, AE; Torres, D; Truong, T; Tung, N; Vachon, CM; van Asperen, CJ; van den Ouweland, AMW; van Rensburg, EJ; Vega, A; Viel, A; Wang, Q; Wappenschmidt, B; Weitzel, JN; Wendt, C; Winqvist, R; Yang, XR; Yannoukakos, D; Ziogas, A; Kraft, P; Antoniou, AC; Zheng, W; Easton, DF; Milne, RL; Beesley, J; Chenevix-Trench, G (2019-04-15)
    Genome-wide association studies (GWAS) have identified more than 170 breast cancer susceptibility loci. Here we hypothesize that some risk-associated variants might act in non-breast tissues, specifically adipose tissue ...
  • No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing. 

    Easton, DF; Lesueur, F; Decker, B; Michailidou, K; Li, J; Allen, J; Luccarini, C; Pooley, KA; Shah, M; Bolla, MK; Wang, Q; Dennis, J; Ahmad, J; Thompson, ER; Damiola, F; Pertesi, M; Voegele, C; Mebirouk, N; Robinot, N; Durand, G; Forey, N; Luben, RN; Ahmed, S; Aittomäki, K; Anton-Culver, H; Arndt, V; Baynes, C; Beckman, MW; Benitez, J; Van Den Berg, D; Blot, WJ; Bogdanova, NV; Bojesen, SE; Brenner, H; Chang-Claude, J; Chia, KS; Choi, JY; Conroy, DM; Cox, A; Cross, SS; Czene, K; Darabi, H; Devilee, P; Eriksson, M; Fasching, PA; Figueroa, J; Flyger, H; Fostira, F; García-Closas, M; Giles, GG; Glendon, G; González-Neira, A; Guénel, P; Haiman, CA; Hall, P; Hart, SN; Hartman, M; Hooning, MJ; Hsiung, CN; Ito, H; Jakubowska, A; James, PA; John, EM; Johnson, N; Jones, M; Kabisch, M; Kang, D; Kosma, VM; Kristensen, V; Lambrechts, D; Li, N; Lindblom, A; Long, J; Lophatananon, A; Lubinski, J; Mannermaa, A; Manoukian, S; Margolin, S; Matsuo, K; Meindl, A; Mitchell, G; Muir, K; Nevelsteen, I; van den Ouweland, A; Peterlongo, P; Phuah, SY; Pylkäs, K; Rowley, SM; Sangrajrang, S; Schmutzler, RK; Shen, CY; Shu, XO; Southey, MC; Surowy, H; Swerdlow, A; Teo, SH; Tollenaar, RA; Tomlinson, I; Torres, D; Truong, T; Vachon, C; Verhoef, S; Wong-Brown, M; Zheng, W; Zheng, Y; Nevanlinna, H; Scott, RJ; Andrulis, IL; Wu, AH; Hopper, JL; Couch, FJ; Winqvist, R; Burwinkel, B; Sawyer, EJ; Schmidt, MK; Rudolph, A; Dörk, T; Brauch, H; Hamann, U; Neuhausen, SL; Milne, RL; Fletcher, O; Pharoah, PD; Campbell, IG; Dunning, AM; Le Calvez-Kelm, F; Goldgar, DE; Tavtigian, SV; Chenevix-Trench, G (2016-05)
    BRCA1 interacting protein C-terminal helicase 1 (BRIP1) is one of the Fanconi Anaemia Complementation (FANC) group family of DNA repair proteins. Biallelic mutations in BRIP1 are responsible for FANC group J, and previous ...
  • Assessment of the Spatial Heterogeneity of Breast Cancers: Associations Between Computed Tomography and Immunohistochemistry. 

    Woolf, DK; Li, SP; Detre, S; Liu, A; Gogbashian, A; Simcock, IC; Stirling, J; Kosmin, M; Cook, GJ; Siddique, M; Dowsett, M; Makris, A; Goh, V (2019)
    Background: Tumour heterogeneity is considered an important mechanism of treatment failure. Imaging-based assessment of tumour heterogeneity is showing promise but the relationship between these mathematically derived ...
  • Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial. 

    Sonnenblick, A; Bailey, A; Uziely, B; Untch, M; Smith, I; Gianni, L; Baselga, J; Jackisch, C; Cameron, D; Bell, R; Zardavas, D; Al-Sakaff, N; Gelber, RD; Dowsett, M; Leyland-Jones, B; Piccart-Gebhart, MJ; DE Azambuja, E (2019-02)
    BACKGROUND/AIM: This study sought to determine whether an autoimmune background could identify patients with HER2-positive early breast cancer (EBC) who derive differential benefit from primary adjuvant trastuzumab-based ...
  • Night shift work and risk of breast cancer in women: the Generations Study cohort. 

    Jones, ME; Schoemaker, MJ; McFadden, EC; Wright, LB; Johns, LE; Swerdlow, AJ (2019-07)
    BACKGROUND: It is plausible that night shift work could affect breast cancer risk, possibly by melatonin suppression or circadian clock disruption, but epidemiological evidence is inconclusive. METHODS: Using serial ...
  • Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation. 

    van Weverwijk, A; Koundouros, N; Iravani, M; Ashenden, M; Gao, Q; Poulogiannis, G; Jungwirth, U; Isacke, CM (2019-06-20)
    The different stages of the metastatic cascade present distinct metabolic challenges to tumour cells and an altered tumour metabolism associated with successful metastatic colonisation provides a therapeutic vulnerability ...
  • Dissecting PARP inhibitor resistance with functional genomics. 

    Pettitt, SJ; Lord, CJ (2019-04-04)
    The poly-(ADP-ribose) polymerase (PARP) inhibitor (PARPi) olaparib was the first licenced cancer drug that targeted an inherited form of cancer, namely ovarian cancers caused by germline BRCA1 or BRCA2 gene mutations. ...
  • Beyond DNA repair: the novel immunological potential of PARP inhibitors. 

    Chabanon, RM; Soria, J-C; Lord, CJ; Postel-Vinay, S (2019)
    Loss of excision repair cross-complementation group 1 (ERCC1), frequently found in lung cancer, and mutations in breast cancer type 1/2 susceptibility genes (BRCA1/2), often found in ovarian, breast and prostate cancers, ...
  • Integration of RNAi and Small Molecule Screens to Identify Targets for Drug Development. 

    Drosopoulos, K; Linardopoulos, S (2019)
    Cellular models for siRNA and small molecule high-throughput screening have been widely used in the last decade to identify targets for drug discovery. As an example, we present a twofold readout approach based on cell ...
  • Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. 

    Sestak, I; Martín, M; Dubsky, P; Kronenwett, R; Rojo, F; Cuzick, J; Filipits, M; Ruiz, A; Gradishar, W; Soliman, H; Schwartzberg, L; Buus, R; Hlauschek, D; Rodríguez-Lescure, A; Gnant, M (2019-07)
    PURPOSE: EndoPredict (EPclin) is a prognostic test validated to inform decisions on adjuvant chemotherapy to endocrine therapy alone for patients with oestrogen receptor-positive, HER2-negative breast cancer. Here, we ...
  • Targeting the PI3-kinase pathway in triple negative breast cancer. 

    Pascual, J; Turner, NC (2019-05-03)
    Triple negative breast cancer (TNBC) is characterised by poor outcomes and a historical lack of targeted therapies. Dysregulation of signalling through the PI3 kinase and AKT signalling pathway is one of the most frequent ...
  • Association analyses identify 31 new risk loci for colorectal cancer susceptibility. 

    Law, PJ; Timofeeva, M; Fernandez-Rozadilla, C; Broderick, P; Studd, J; Fernandez-Tajes, J; Farrington, S; Svinti, V; Palles, C; Orlando, G; Sud, A; Holroyd, A; Penegar, S; Theodoratou, E; Vaughan-Shaw, P; Campbell, H; Zgaga, L; Hayward, C; Campbell, A; Harris, S; Deary, IJ; Starr, J; Gatcombe, L; Pinna, M; Briggs, S; Martin, L; Jaeger, E; Sharma-Oates, A; East, J; Leedham, S; Arnold, R; Johnstone, E; Wang, H; Kerr, D; Kerr, R; Maughan, T; Kaplan, R; Al-Tassan, N; Palin, K; Hänninen, UA; Cajuso, T; Tanskanen, T; Kondelin, J; Kaasinen, E; Sarin, A-P; Eriksson, JG; Rissanen, H; Knekt, P; Pukkala, E; Jousilahti, P; Salomaa, V; Ripatti, S; Palotie, A; Renkonen-Sinisalo, L; Lepistö, A; Böhm, J; Mecklin, J-P; Buchanan, DD; Win, A-K; Hopper, J; Jenkins, ME; Lindor, NM; Newcomb, PA; Gallinger, S; Duggan, D; Casey, G; Hoffmann, P; Nöthen, MM; Jöckel, K-H; Easton, DF; Pharoah, PDP; Peto, J; Canzian, F; Swerdlow, A; Eeles, RA; Kote-Jarai, Z; Muir, K; Pashayan, N; PRACTICAL consortium; Harkin, A; Allan, K; McQueen, J; Paul, J; Iveson, T; Saunders, M; Butterbach, K; Chang-Claude, J; Hoffmeister, M; Brenner, H; Kirac, I; Matošević, P; Hofer, P; Brezina, S; Gsur, A; Cheadle, JP; Aaltonen, LA; Tomlinson, I; Houlston, RS; Dunlop, MG (2019-05-14)
    Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide, and has a strong heritable basis. We report a genome-wide association analysis of 34,627 CRC cases and 71,379 controls of European ancestry that ...
  • Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37298 women with early breast cancer in 26 randomised trials 

    Boddington, C; Bradley, R; Braybrooke, J; Burrett, J; Clarke, M; Davies, C; Davies, L; Dodwell, D; Duane, F; Evans, V; Gettins, L; Godwin, J; Gray, R; Hills, R; James, S; Liu, H; Liu, Z; MacKinnon, E; Mannu, G; McGale, P; McHugh, T; Morris, P; Pan, H; Peto, R; Read, S; Taylor, C; Wang, Y; Wang, Z; Bradley, R; Braybrooke, J; Gray, R; Bergh, J; Peto, R; Gray, R; Bradley, R; Braybrooke, J; Liu, Z; Peto, R; Davies, L; Dodwell, D; McGale, P; Pan, H; Taylor, C; Barlow, W; Bliss, J; Bruzzi, P; Cameron, D; Fountzilas, G; Loibl, S; Mackey, J; Martin, M; Del Mastro, L; Moebus, V; Nekljudova, V; De Placido, S; Swain, S; Untch, M; Pritchard, KI; Bergh, J; Norton, L; Fasching, P; Harbeck, N; Untch, M; Piedbois, P; Gnant, M; Steger, G; Di Leo, A; Dolci, S; Francis, P; Larsimont, D; Nogaret, JM; Philippson, C; Piccart-Gebhart, MJ; Linn, S; Peer, P; Tjan-Heijnen, V; Vliek, S; Mackey, J; Martin, M; Slamon, D; Bartlett, JMS; Bramwell, VH; Chen, BE; Chia, SKL; Gelmon, K; Goss, PE; Levine, MN; Parulekar, W; Pater, JL; Pritchard, KI; Rakovitch, E; Shepherd, LE; Tu, D; Whelan, T; Berry, D; Broadwater, G; Cirrincione, C; Muss, H; Norton, L; Weiss, RB; Shan, Y; Shao, YF; Wang, X; Xu, B; Zhao, DB; Bartelink, H; Bijker, N; Bogaerts, J; Cardoso, F; Cufer, T; Julien, JP; Poortmans, PM; Rutgers, E; van de Velde, CJH; Carrasco, E; Martin, M; Segui, MA; Blohmer, JU; Costa, SD; Gerber, B; Jackisch, C; Loibl, S; Nekljudova, V; von Minckwitz, G; Bruzzi, P; Giuliano, M; De laurentiis, M; De Placido, S; Del Mastro, L; Bamia, C; Fountzilas, G; Koliou, G-A; Mavroudis, D; A'Hern, R; Bliss, J; Cameron, D; Ellis, P; Kilburn, L; Morden, J; Yarnold, JR; Sadoon, M; Tulusan, AH; Anderson, S; Bass, G; Costantino, J; Dignam, J; Fisher, B; Geyer, C; Mamounas, EP; Paik, S; Redmond, C; Swain, S; Wickerham, L; Wolmark, N; Del Mastro, L; Venturini, M; Bighin, C; Bruzzi, P; Del Mastro, L; Pastorino, S; Pronzato, P; Sertoli, MR; Barlow, W; Bergh, J; Foukakis, T; Pritchard, KI; Swain, S; Cameron, D; Albain, K; Anderson, S; Arriagada, R; Barlow, W; Bartlett, J; Bergsten-Nordstrom, E; Bliss, J; Boccardo, F; Bradley, R; Brain, E; Braybrooke, J; Carey, L; Clarke, M; Coates, A; Coleman, R; Correa, C; Costantino, J; Cuzick, J; Davidson, N; Davies, C; Davies, L; Di Leo, A; Dodwell, D; Dowsett, M; Duane, F; Ewertz, M; Forbes, J; Francis, P; Gelber, R; Gnant, M; Goldhirsch, A; Goodwin, P; Gray, R; Hayes, D; Hill, C; Ingle, J; Jagsi, R; Janni, W; Liu, Z; Loibl, S; MacKinnon, E; Mannu, G; Martin, M; McGale, P; Mukai, H; Nekljudova, V; Norton, L; Ohashi, Y; Paik, S; Pan, H; Peto, R; Piccart, M; Pierce, L; Poortmans, P; Raina, V; Ravdin, P; Rea, D; Regan, M; Robertson, J; Rutgers, E; Slamon, D; Sparano, J; Steger, G; Taylor, C; Tutt, A; Viale, G; Wang, X; Whelan, T; Wilcken, N; Wolmark, N; Wood, W; Zambetti, M; EBCTCG (2019-04-06)
  • Molecular residual disease and adjuvant trials design in solid tumors. 

    Coakley, M; Garcia-Murillas, I; Turner, NC (2019-05-14)
    Advances in diagnosis and treatment have resulted in a high rate of survival for many patients with early stage cancers. However, identifying who is at ongoing risk of relapse remains of high priority to direct subsequent ...
  • Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer. 

    Diéras, V; Rugo, HS; Schnell, P; Gelmon, K; Cristofanilli, M; Loi, S; Colleoni, M; Lu, DR; Mori, A; Gauthier, E; Huang Bartlett, C; Slamon, DJ; Turner, NC; Finn, RS (2019-04-01)
    BACKGROUND: Palbociclib administered with endocrine therapy was tolerable when the overall incidence of toxicities was assessed separately for three PALOMA studies. This study analyzed pooled, longer-term PALOMA safety ...
  • BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. 

    Turner, NC; Alarcón, E; Armstrong, AC; Philco, M; López Chuken, YA; Sablin, M-P; Tamura, K; Gómez Villanueva, A; Pérez-Fidalgo, JA; Cheung, SYA; Corcoran, C; Cullberg, M; Davies, BR; de Bruin, EC; Foxley, A; Lindemann, JPO; Maudsley, R; Moschetta, M; Outhwaite, E; Pass, M; Rugman, P; Schiavon, G; Oliveira, M (2019-05-01)
    BACKGROUND: BEECH investigated the efficacy of capivasertib (AZD5363), an oral inhibitor of AKT isoforms 1-3, in combination with the first-line weekly paclitaxel for advanced or metastatic estrogen receptor-positive ...

View more